Difference between revisions of "Ponatinib (Iclusig)"
Jump to navigation
Jump to search
(updated links) |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Tyrosine kinase inhibitor with multiple targets, including Bcr-Abl tyrosine kinase, the constitutively active tyrosine kinase resulting from the Philadelphia chromosome abnormality in CML, as well as VEGFR, PDGFR, FGFR, the SRC kinases, KIT, EPH receptors, RET, TIE2, and FLT3. Ponatinib is active against the Bcr-Abl T315I mutation.<ref name="insert">[https://www.iclusig.com/pdf/ICLUSIG-Prescribing-Information.pdf Ponatinib (Iclusig) package insert]</ref><ref>[[:File:Ponatinib.pdf | Ponatinib (Iclusig) package insert (locally hosted backup)]]</ref><ref>[http://iclusig.com/ Iclusig manufacturer's website | + | Class/mechanism: Tyrosine kinase inhibitor with multiple targets, including Bcr-Abl tyrosine kinase, the constitutively active tyrosine kinase resulting from the Philadelphia chromosome abnormality in CML, as well as VEGFR, PDGFR, FGFR, the SRC kinases, KIT, EPH receptors, RET, TIE2, and FLT3. Ponatinib is active against the Bcr-Abl T315I mutation.<ref name="insert">[https://www.iclusig.com/pdf/ICLUSIG-Prescribing-Information.pdf Ponatinib (Iclusig) package insert]</ref><ref>[[:File:Ponatinib.pdf | Ponatinib (Iclusig) package insert (locally hosted backup)]]</ref><ref>[http://iclusig.com/ Iclusig manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 11: | Line 11: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | * | + | *[https://www.iclusig.com/pdf/ICLUSIG-Prescribing-Information.pdf Ponatinib (Iclusig) package insert]<ref name="insert"></ref> |
| + | *[https://chemocare.com/chemotherapy/drug-info/ponatinib.aspx Ponatinib (Iclusig) patient drug information (Chemocare)]<ref>[https://chemocare.com/chemotherapy/drug-info/ponatinib.aspx Ponatinib (Iclusig) patient drug information (Chemocare)]</ref> | ||
| + | *[http://www.uptodate.com/contents/ponatinib-patient-drug-information Ponatinib (Iclusig) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ponatinib-patient-drug-information Ponatinib (Iclusig) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
Revision as of 23:47, 31 December 2021
General information
Class/mechanism: Tyrosine kinase inhibitor with multiple targets, including Bcr-Abl tyrosine kinase, the constitutively active tyrosine kinase resulting from the Philadelphia chromosome abnormality in CML, as well as VEGFR, PDGFR, FGFR, the SRC kinases, KIT, EPH receptors, RET, TIE2, and FLT3. Ponatinib is active against the Bcr-Abl T315I mutation.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Ponatinib (Iclusig) package insert[1]
- Ponatinib (Iclusig) patient drug information (Chemocare)[4]
- Ponatinib (Iclusig) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 12/14/2012: Accelerated approval for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy (Based on OPTIC)
- 12/14/2012: Accelerated approval for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. (Based on PACE)
- 11/29/2016: Granted full approval for the treatment of adult patients with chronic-phase, accelerated-phase, or blast-phase chronic myeloid leukemia (CML) or Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL) for whom no other tyrosine kinase inhibitor therapy is indicated
- 11/29/2016: Granted full approval for the treatment of adult patients with T315I–positive CML (chronic phase, accelerated phase, or blast phase)
- 11/29/2016: Granted full approval for the treatment of adult patients with T315I-positive, Philadelphia chromosome–positive ALL.
REMS program
- 10/31/2013: Suspended by FDA because of the risk of life-threatening blood clots and severe narrowing of blood vessels.
- 12/20/2013: REMS program put in place and medication is once again available.
Also known as
- Code name: AP24534
- Generic name: ponatinib hydrochloride
- Brand name: Iclusig
References
Categories:
- Drugs
- Oral medications
- Mutation-specific medications
- Bcr-Abl inhibitors
- FGFR inhibitors
- FLT3 inhibitors
- KIT inhibitors
- RET inhibitors
- SRC inhibitors
- VEGFR inhibitors
- PDGFR inhibitors
- B-cell acute lymphoblastic leukemia medications
- Chronic myelogenous leukemia medications
- REMS program
- FDA approved in 2012
- PMDA approved drugs